Please ensure Javascript is enabled for purposes of website accessibility

Alexion Pharmaceuticals to Initiate Phase 3 Study for Ultomiris as a Potential Coronavirus Treatment

By Prosper Junior Bakiny – Apr 20, 2020 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The trial will start in May and will enroll 270 patients with severe cases of COVID-19.

Alexion Pharmaceuticals (ALXN) recently announced that it would initiate a phase 3 study to investigate the safety and efficacy of Ultomiris as a treatment for COVID-19. Ultomiris is already approved for the treatment of paroxysmal nocturnal hemoglobinuria, a rare blood disease that causes red blood cells to break apart and release hemoglobin, the component in red blood cells that carries oxygen around the body. This drug has been used on a compassionate basis to treat COVID-19 patients, and the results have, so far, been encouraging, which is why Alexion is launching a formal clinical trial.

This study, which is set to start in May, will enroll about 270 patients in several countries that have been severely impacted by the ongoing outbreak. It will focus on patients with severe manifestations of COVID-19, namely "those who are hospitalized with severe pneumonia or acute respiratory distress syndrome."

Face mask with COVID-19 written on it.

Image Source: Getty Images.

Several other pharma companies are currently pursuing potential treatments for COVID-19, among them Gilead Sciences (GILD -2.19%). Back in February, it initiated two phase 3 clinical trials to study the efficacy of its antiviral drug, remdesivir, as a potential treatment for COVID-19. The company enrolled about 1,000 patients in multiple countries, including 400 patients with severe manifestations of COVID-19, and 600 patients with mild manifestations of the disease. Patients received either five or 10 doses of remdesivir.

While we don't have data from these clinical trials yet, early anecdotal results from the arm of a remdesivir study being conducted at  University of Chicago Medicine were encouraging. According to STAT, an online trade publication that focuses on the healthcare sector, among 125 patients who were treated with remdesivir, most had been released from the hospital, and only two died. 

However, even the doctor heading the overseeing the remdesivir study at University of Chicago Hospital warned that it was too early to draw definitive conclusions, and because the study does not include a control/placebo arm, interpreting the results will be more difficult.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$61.69 (-2.19%) $-1.38
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.